zurück
Lenvatinib (new indication: endometrial carcinoma, after platinum-based therapy, in combination with pembrolizumab)
Subject:
- Active Substance: Lenvatinib
- Name: Lenvima®
- Therapeutic area: Endometrial carcinoma
- Pharmaceutical company: Eisai GmbH
Time table:
- Start: 15.01.2022
- Final decision by G-BA: 07.07.2022
Final decision:
- Indication for a considerable additional benefit